Loading patent…
AssigneesHopitaux Universitaires de Strasbourg, lNSERM-lnstitut National de la Santé et de la Recherche Médicale
InventorsEduardo ANGLES-CANO, Ferhat MEZIANI, Florence TOTI
Estimating the term…
The invention relates to an in-vitro process for predicting and/or detecting fibrinolytic insufficiency, preferably associated to pathologies and NETs with/without disseminated intravascular coagulation (DIC), or from a first biological sample comprising measuring the concentration of plasminogen and/or at least one fragment thereof. The invention also relates to a process for determining the efficiency of a treatment of fibrinolytic insufficiency and to plasminogen and pharmaceutical composition comprising plasminogen for use as a drug in the treatment of fibrinolytic insufficiency, preferably associated to septic shock and disseminated intravascular coagulation (DIC).
An in-vitro process for predicting and/or detecting fibrinolytic insufficiency, preferably associated to pathologies with NETs with/without disseminated intravascular coagulation (DIC), from a first biological sample comprising measuring the concentration of Plasminogen and/or at least one fragment thereof.
An in-vitro process for determining the efficacy of a treatment of fibrinolytic insufficiency, in particular associated to DIC comprising:
Plasminogen for use as a drug in the treatment of fibrinolytic insufficiency, preferably associated to disseminated intravascular coagulation (DIC).
Pharmaceutical composition comprising plasminogen for use as a medicament in the treatment of fibrinolytic insufficiency preferably associated to disseminated intravascular coagulation (DIC).
Plasminogen for use as a drug in the treatment of fibrinolytic insufficiency preferably associated to disseminated intravascular coagulation (DIC) linked to moderate/severe plasminogen consumption/deficiency, particularly in patients with sepsis.
Dependencies are inferred from the claim text.